Literature DB >> 1882800

Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy.

S Terasaki1, Y Nakanuma, H Ogino, M Unoura, K Kobayashi.   

Abstract

Recently, there have been reports that ursodeoxycholic acid (UDCA) therapy has a beneficial effect on liver function in patients with primary biliary cirrhosis. However, information regarding the effects of UDCA therapy on hepatic histology remains insufficient. Aberrant expression of HLA antigens on hepatocytes is regarded important in the progression of hepatocellular damages mediated by cytotoxic T-cells in primary biliary cirrhosis. In this study, we examined immunohistochemically hepatocellular expression of HLA antigens on hepatocytes before and after UDCA therapy in four patients with asymptomatic primary biliary cirrhosis. Piecemeal necrosis, intralobular focal necrosis, and portal inflammation, as well as infiltration of activated T-lymphocytes and expression of HLA class I antigens on hepatocytes, disappeared, or diminished in parallel after the therapy. In two of four patients, expression of HLA-DR on some periportal hepatocytes before the therapy also disappeared after the therapy. These observations imply that UDCA therapy decreases the hepatocellular expression of HLA antigens and thereby reduces or abolishes T-cell-mediated hepatocellular necrosis in primary biliary cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1882800

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

Review 1.  Primary biliary cirrhosis: new perspectives in diagnosis and treatment.

Authors:  M I Prince; D E Jones
Journal:  Postgrad Med J       Date:  2000-04       Impact factor: 2.401

Review 2.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 3.  Ursodeoxycholic acid in the treatment of liver diseases.

Authors:  S Saksena; R K Tandon
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

Review 4.  Use of ursodeoxycholic acid in patients with liver disease.

Authors:  Paul Angulo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

5.  Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.

Authors:  R Saeki; H Ogino; S Kaneko; M Unoura; K Kobayashi
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

Review 6.  Primary biliary cholangitis: pathogenesis and therapeutic opportunities.

Authors:  Aliya F Gulamhusein; Gideon M Hirschfield
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-12-09       Impact factor: 46.802

7.  Effects of ursodeoxycholic acid and chenodeoxycholic acid on major histocompatibility complex class I gene expression.

Authors:  F Hirano; H Tanaka; Y Makino; K Okamoto; I Makino
Journal:  J Gastroenterol       Date:  1996-02       Impact factor: 7.527

8.  Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial.

Authors:  Xiao-Li Pan; Li Zhao; Liang Li; Ai-Hua Li; Jin Ye; Ling Yang; Ke-Shu Xu; Xiao-Hua Hou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17

9.  Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis.

Authors:  Y Nishigaki; H Ohnishi; H Moriwaki; Y Muto
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

10.  Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity.

Authors:  Suleyman Uraz; Veysel Tahan; Cem Aygun; Fatih Eren; Goksenin Unluguzel; Meral Yuksel; Omer Senturk; Erol Avsar; Goncagul Haklar; Cigdem Celikel; Sadettin Hulagu; Nurdan Tozun
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.